Chinese pharma cost edge beats Pentagon blacklist

Analysts say WuXi AppTec's Pentagon blacklisting won't deter multinational drug makers from partnering with Chinese biopharma firms, as cost advantages remain key. The move highlights geopolitical tensions in the sector.